Introduction
============

Multiple sclerosis (MS) is a neurodegenerative disease, characterized by inflammation and demyelination. It is the second common reason for disability in young adults. MS affects three folds more in women than men ([@B39]). It often occurs in high-income countries with a heterogeneous prevalence worldwide (over 2,000,000 people around the world). MS has the highest prevalence in North America (140/100,000 population) and Europe (108/100,000), and the lowest in East Asia (2.2/100,000 population) and sub-Saharan Africa (2.1/100,000). So, the majority of countries encounter MS as a disabling disease ([@B18]; [@B13]).

Various environmental (geographical, infectious, and/or nutritional) and genetic factors are involved in MS. Therefore, it is recognized as a multifactorial disease ([@B5]). Pathogenesis of the disease is not well known but the hallmark of MS is lesions caused by infiltration of immune cells from the blood--brain barrier (BBB), and then enhances inflammation, demyelination, and neurodegeneration in the central nervous system.

The inflammatory process involves different immune cells such as Th1, Th2, macrophage, and B cells ([@B18]; [@B37]). Since inflammation is considered as a main cause of MS, anti-inflammatory, and immunomodulatory drugs are among the primary therapeutic choices. Approved anti-inflammatory treatments for MS include injectable therapies \[interferon-β (IFN-β) and glatiramer acetate\], oral therapies (e.g., teriflunomide, dimethyl fumarate, and fingolimod), and infusion therapies (mitoxantrone, natalizumab, and alemtuzumab) ([@B16]).

Another possible cause of pathogenesis is oxidative stress. Mitochondrial DNA and proteins are extremely vulnerable to oxidative damage. Mitochondrial changes are the reason for oligodendrocytes apoptosis in MS ([@B23]; [@B40]). Therefore, antioxidant treatments can protect oligodendrocytes and neurons.

The role of matrix metalloproteinases (MMPs) has been extensively investigated in the pathogenesis of MS. The studies revealed that MMPs (types II, VII, IX, and XII) secreted from leukocytes, microglia, neurons, and reactive astrocytes digest myelin basic protein which lead to axonal demyelination, neuronal cell death, and MS progression. In addition, MMPs are the main cause of disrupting the BBB integrity which facilitates immune cells migration into the brain. Therefore, MMP inhibitors can contribute to the improvement of MS. Some synthetic inhibitors and drugs such as minocycline and [D]{.smallcaps}-penicillamine have been investigated in this regard so far ([@B25]).

Lastly, neuronal damage in MS lesions has been reported in neuropathological research. Mechanisms causing myelin destruction are not entirely known. Typically, MS lesions consist of the BBB breakdown, multifocal inflammation, demyelination, oligodendrocyte damage, axonal degeneration, and neuron loss. This damage is likely to be a result of inflammation in the CNS ([@B4]). Therefore, the protection of neurons from possible damage and inducing neurogenesis and myelogenesis in the CNS are therapeutic targets which overcome the MS challenges.

Altogether, it seems that a drug with anti-inflammatory, oxidative stress inhibitory, MMPs inhibitory, and neurogenesis stimulatory properties may be effective for the treatment of MS. There is some evidence which Bryostatin-1 (a macrolide and marine natural product) is a therapeutic choice for MS.

Supporting Evidences of Hypothesis
==================================

Evidence 1: Anti-inflammation
-----------------------------

T helper cells are one of the important components of the immune system. T helper cells have various phenotypes include Th1, Th2, Th17, and T~regs~; each one has its specific roles. Th1 participates in inflammatory processes. In MS, the early event in the initiation of inflammation in the brain is the migration of activated T cells through the BBB. Activated Th1 cells stimulate cytokines such as TNF-α, IFN-γ, and IL-2 which are expressed in MS lesions. Th2 is involved in anti-inflammatory processes by different cytokines production such as IL-5 and IL-10 ([@B8]).

*In vivo* experiments have shown that Bryostatin-1 is able to enhance Th2 responses and significantly increase Th2 cytokines levels such as IL-5 and IL-10. So, Bryostatin-1 shifts the immune response toward Th2 type profile which is associated with immunological tolerance ([@B1]). One of the most known mechanisms in inflammatory reactions is up-regulation of cyclooxygenase-2 (COX-2). It has been recently shown that treatment with Bryostatin-1 can sharply down-regulate the mRNA expression level of COX-2 ([@B27]).

[@B9] recently showed that Bryostatin-1 enhances an anti-inflammatory phenotype in macrophages and APCs. They observed that Bryostatin-1 up-regulates CD86 (a costimulatory protein required for activation of T cells upon their binding to APCs) in bone marrow-derived dendritic cells (BMDCs), whereas it has no significant effect on CD40 (a costimulatory protein necessary for pro-inflammatory activation of APCs). Moreover, Bryostatin-1 treatment of murine peritoneal macrophages promotes the IL-4-induced expression of arginase-1, a marker of the anti-inflammatory and repair-promoting M2 macrophage phenotype. Similar to its effect on dendritic cells, low-dose of Bryostatin-1 inhibits secretion of proinflammatory cytokines such as IL-12 and IL-6. In contrast, Bryostatin-1 considerably increases secretion of IL-10, an anti-inflammatory cytokine that inhibits Th1 differentiation and stimulates an immunoregulatory environment ([@B9]).

Also, a higher level of TNF-α released by stimulation of Th1 cells causes more BBB damage ([@B10]). [@B3] found that treatment with Bryostatin-1 leads to a significant decrease of BBB permeability caused by TNF-α.

Evidence 2: Anti-oxidant Property
---------------------------------

The production of free radicals like hydroxyl radical (-OH) and hydrogen peroxide (H~2~O~2~) is one of the causes of cellular damage. If the antioxidant defense does not have the capability of scavenging free radicals, they induce cell death in neural cells ([@B20]).

[@B29] studied the anti-oxidant effect of Bryostatin-1. Their results revealed that pre-treatment of cultured cells with Bryostatin-1 inhibit H~2~O~2~ induced cell death. Caspases after activation by mitochondria play an important role in the regulation of cell apoptosis. Bryostatin-1 can inhibit apoptosis in some cells via a reduction in the activation of caspase-3 and -9. Bcl-2 is another factor involved in the regulation of apoptosis by mitochondrial pathway. Bryostatin-1 is able to increase the expression level of Bcl-2 as an anti-apoptotic factor ([@B29]). In a study conducted by [@B32], there was a synergistic effect between Bryostatin-1 and α-tocopherol to reduce oxidative stress damage in neural cells.

Evidence 3: Suppression of Matrix Metalloproteinases Expression
---------------------------------------------------------------

Matrix metalloproteinases (MMPs) are involved in extracellular matrix (ECM) degradation, cell apoptosis, and degradation of the basement membrane ([@B21]; [@B22]). MMPs cause damage to the brain in MS through two mechanisms: first, MMPs produced by leukocytes degrade vessel endothelial lining and result in BBB breakdown and the entrance of inflammatory cells to CNS. Second, MMPs can damage the myelin sheath and cause more demyelination and inflammation into the CNS ([@B7]). Treatment with Bryostatin-1 suppresses production of MMP-1, -3, -9, -10, and 11 ([@B11]; [@B26]). Also, it has been reported that Bryostatin-1 reduces the hemorrhagic transformation following ischemic/reperfusion injuries and improves BBB disruption by down-regulation of MMP-9 expression and activation ([@B35]). [@B30] reported that Bryostatin-1 is noticeably able to suppress the expression of MMP-2 and MMP-9 in a breast cancer cell line.

Evidence 4: Neuroprotective Effects
-----------------------------------

[@B36] showed that Bryostatin-1 is able to attenuate both necrotic and apoptotic cell death of neurons in ischemic brain injury. Furthermore, Bryostatin-1 ameliorates neurological functions and decreases inflammatory responses. Therefore, it is a neuroprotective agent ([@B36]). In addition to inhibition of cell death, Bryostatin-1 neuroprotective effects may be due to the increase of the neurotrophin production in neural cells ([@B19]).

By studying an animal model of traumatic brain injury (TBI), [@B15] found that Bryostatin-1 decreases toxic PKCα levels and increases neuroprotective isozyme PKC𝜀. Also, because of PKC isozymes modulation, it reduces BBB breakdown by a notable rise in the tight junction proteins including VE-cadherin, ZO-1, and occluding ([@B12]; [@B15]). It has been revealed that Bryostatin-1 is able to induce neurite regrowth of spiral ganglion neurons (SGNs) by PKCβI activation mechanism ([@B12]). Moreover, Bryostatin shows a neuroprotective effect on auditory neurons ([@B24]).

The elevated α-Synuclein expression in oligodendrocytes has been shown in an animal model of MS. The abnormal α-Synuclein accumulation in cells probably contributes to oligodendrocytes death in MS. Moreover, [@B14] demonstrated that α-Synuclein is present in the active inflammatory lesions of MS. It has been shown that the treatment with Bryostatin-1 causes a significant reduction in α-synuclein expression ([@B30]).

Evidence 5: Neurogenesis
------------------------

Recent studies make evident that the administration of Bryostatin-1 after global ischemic insult in the brain results in curative neurogenesis, synaptogenesis, and cognitive improvement ([@B36]).

In an animal model, [@B33] showed that Bryostatin-1 administration improves deficits in neurotrophic activity and synaptogenesis after ischemia. Bryostatin-1 ameliorates learning and memory by preventing neuronal damage and restoring the dendritic spines and their synapses ([@B33]). Bryostatin-1 promotes exercise-dependent paralysis recovery in animals with stroke. It is possibly related to the synaptic conduction efficiency and synaptic plasticity ([@B17]). Therefore, Bryostatin-1 has neurogenesis and synaptogenic effects which can overcome memory impairment as a common problem in MS ([@B2]).

Evidence 6: Differentiation of OPCs as a Critical Step for Remyelination/Myelogenesis
-------------------------------------------------------------------------------------

Previous results showed that myelin proteins, which accumulate following demyelination, inhibit remyelination by inhibition of oligodendrocyte progenitor cells (OPCs) differentiation into myelinating oligodendrocyte via PKCα modulation. Bryostatin-1 has been shown to overcome the inhibitory effects of myelin protein extracts on OPC differentiation and induce direct differentiation of oligodendrocyte progenitor stem cells into myelinating oligodendrocyte via inhibition of PKCα ([@B6]).

Hypothesis
==========

Regarding the provided evidences, we hypothesize here that Bryostatin-1 could be used to treat MS due to its anti-inflammatory, anti-oxidant, neuroprotective, neurogenesis, and inhibition of metalloproteinase matrix properties (**Figure [1](#F1){ref-type="fig"}**).

![Anti-inflammatory, anti-oxidant, neuroprotective, neurogenesis, and inhibition of MMPs properties of Bryostatin-1.](fphar-09-00625-g001){#F1}

Evaluation of Hypothesis
------------------------

To evaluate the hypothesis, it is necessary to do some *in vitro* and *in vivo* experimental studies which can address the building block questions of the hypothesis.

### *In Vitro* Studies

To evaluate the neuroprotective and anti-oxidant properties of Bryostatin-1, oligodendrocyte cell line such as the OLN-93 will be cultured and oxidative stress and cell death will be induced by H~2~O~2~ or cuprizone. The viability tests (and qualitative and quantitative analysis of apoptotic markers) and the measurement of neurotrophin levels and mitochondrial assays before and after treatment with Bryostatin-1 give us some useful information about the effects of Bryostatin-1 on the mechanisms involved in MS such as oxidative stress.

### *In Vivo* Studies

To evaluate the *in vivo* effects of Bryostatin-1, the toxic model of MS is created in C57BL/6 mice by cuprizone. In order to measure the motor coordination and balance, the behavioral test of rotarod will be carried out before and after treatment with Bryostatin-1. Cellular and molecular tests using immunohistochemistry, Western blot, and real time-PCR analyses on the myelin genes and proteins and microscopic examinations will help us to investigate the effects of Bryostatin-1. To determine the reduction of inflammation by Bryostatin-1, inflammatory, and anti-inflammatory cytokines are measured before and after treatment with Bryostatin-1 via Elisa kits. Also, the effect of Bryostatin-1 on the suppression of the MMPs will be evaluated on the expression levels. Finally, to evaluate the effects of Bryostatin on OPC differentiation and remyelination, oligodendrocyte precursor marker (Olig2) and adult myelin markers (PLP, MBP, and MOG) is examined by real time-PCR and Western blot analyses.

Discussion
==========

Multiple sclerosis is still a challenging disease without a curative treatment ([@B38]). Due to the fact that MS is a complex and multifactorial disease ([@B5]), treatment must be multi-purpose and target simultaneously several pathological features of MS. Currently, the available medications have more effects on inflammatory aspects of MS. We suggested here that Bryostatin-1 has enough criteria to be as a choice for the MS therapy. Since it has anti-inflammatory, anti-oxidant, MMP inhibitory, neuroprotective, and neurogenic properties, it can cover many aspects of the pathogenesis of MS. Bryostatin-1 has been positively used in various animal models and clinical trials of neural injury, including auditory neurodegeneration, ischemic stroke, TBI, and Alzheimer's disease. After global ischemic insult, Bryostatin-1 administration resulted in improvement of cognition, synaptogenesis, and neurogenesis, and decline of necrosis and astrogliosis in infarcted tissue. Moreover, it has direct antitumor effects in lymphoma, sarcoma, leukemia, melanoma, and is used breast, colon, lung, and ovarian cancers ([@B28]; [@B34]). In addition, it has several pharmacological actions including functional restoration and cognitive improvement in dementia and depression, a decline in the accumulation of neurotoxic amyloid and an inhibition of tau protein hyper-phosphorylation. Based on the data accessible in the preclinical and clinical studies, pharmacological and toxicological aspects of Bryostatin-1 have been demonstrated. Bryostatin-1 is well tolerated and its adverse reactions are rare, mild, and reversible. A major advantage of this drug is that it can be administered orally. Furthermore, its biological and elimination half-life is suitable. Today, the synthetic form of Bryostatin-1 is available which is cost-effective. Bryostatin-1 can easily cross the BBB, which is an advantage for treating MS in low doses ([@B31]).

In the end, to the best of our knowledge, the majority of studies about the effects of Bryostatin-1 are on the cellular level. Therefore, it is necessary to focus on the molecular events occurred after treatment of the cells with Bryostatin-1 in the future studies, especially in the field of evidences mentioned in this paper such as oxidative stress, inflammation, myelogenesis and so on.

Conclusion
==========

In conclusion, Bryostatin-1 with anti-inflammatory, anti-oxidant, MMPs inhibitory, and neurogenesis stimulatory properties and other advantages include the ability to cross the BBB and oral availability may be appropriate for the treatment of MS.
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